October 14, 2020
4 min watch
Save
VIDEO: Faricimab a step into new era of longer-lasting retinal disease therapies
At the virtual Euretina congress, Francesco Bandello, MD, speaks about faricimab, a drug that combines anti-VEGF and Ang-2-blocking properties.
The phase 2 BOULEVARD trial for diabetic macular edema and AVENUE and STAIRWAY trials for age-related macular degeneration have shown positive, long-lasting therapeutic effects.
Published by:
Sources/Disclosures
Collapse
Source:
Bandello F. Real-world outcomes of current treatment options for diabetic macular edema: a systematic literature review. Presented at: Euretina congress; Oct. 2-4, 2020 (virtual meeting).
Read more about